Form 8-K - Current report:
SEC Accession No. 0000950170-24-102313
Filing Date
2024-08-30
Accepted
2024-08-30 16:01:07
Documents
21
Period of Report
2024-08-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20240827.htm   iXBRL 8-K 58566
2 EX-10.1 omga-ex10_1.htm EX-10.1 116778
3 EX-10.2 omga-ex10_2.htm EX-10.2 116933
4 EX-10.3 omga-ex10_3.htm EX-10.3 116314
5 EX-10.4 omga-ex10_4.htm EX-10.4 111268
6 EX-10.5 omga-ex10_5.htm EX-10.5 111015
7 GRAPHIC img33839852_0.jpg GRAPHIC 194447
8 GRAPHIC img34763373_0.jpg GRAPHIC 194447
9 GRAPHIC img35686894_0.jpg GRAPHIC 194447
10 GRAPHIC img36610415_0.jpg GRAPHIC 194447
11 GRAPHIC img37533936_0.jpg GRAPHIC 194447
  Complete submission text file 0000950170-24-102313.txt   2182389

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20240827.xsd EX-101.SCH 29129
23 EXTRACTED XBRL INSTANCE DOCUMENT omga-20240827_htm.xml XML 4885
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 241269731
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)